Of the top 5 BJUI papers of 2014, which is your favourite?
Guideline of guidelines: prostate cancer screening – 38.24%
The transcriptional programme of the androgen receptor (AR) in prostate cancer – 11.76%
Phase III, randomised, double‐blind, placebo‐controlled study of the β3‐adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder – 5.88%
Engaging responsibly with social media: the BJUI guidelines – 38.24%
Penile vibratory stimulation in the recovery of urinary continence and erectile function after nerve‐sparing radical prostatectomy: a randomized, controlled trial – 5.88%